RI
RTW Investments Portfolio holdings
AUM
$8.12B
1-Year Est. Return
73.2%
1 Year Est. Return
+73.2%
AUM
$8.12B
AUM Growth
+$1.09B
(+16%)
Holding
83
Top Buys
| 1 | +$76.4M | |
| 2 | +$49.8M | |
| 3 | +$46.6M | |
| 4 |
Xencor
XNCR
|
+$44.8M |
| 5 |
Guardant Health
GH
|
+$39M |
Top Sells
| 1 | +$289M | |
| 2 | +$186M | |
| 3 | +$110M | |
| 4 |
Natera
NTRA
|
+$95.6M |
| 5 |
Alkermes
ALKS
|
+$90.3M |
Sector Composition
| 1 | Healthcare | 99.9% |
| 2 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
UroGen Pharma
URGN
$1.33B
| $90.7M | 1.12% |
4,543,895
|
|
||
27
Intuitive Surgical
ISRG
$201B
| $90.5M | 1.12% |
202,456
|
|
||
28
GH Research
GHRS
$881M
| $79.6M | 0.98% |
5,569,564
+29,107
|
|
||
29
Taysha Gene Therapies
TSHA
$1.21B
| $79.6M | 0.98% |
24,354,291
-667,293
|
|
||
30
Zai Lab
ZLAB
$2.2B
| $77.7M | 0.96% |
2,291,372
-3,245,504
|
|
||
31
Immatics
IMTX
$1.25B
| $75.1M | 0.93% |
8,815,617
+1,845,465
|
|
||
|
32
Xencor
XNCR
$1.18B
| $73M | 0.9% |
6,221,054
+3,818,171
|
|
||
33
CG Oncology
CGON
$3.49B
| $68.5M | 0.84% |
1,701,216
|
|
||
|
BBNX
34
Beta Bionics
BBNX
$1.3B
| $65.6M | 0.81% |
3,299,191
|
|
||
35
Spyre Therapeutics
SYRE
$2.22B
| $60.7M | 0.75% |
3,621,996
|
|
||
36
Rocket Pharmaceuticals
RCKT
$342M
| $57.7M | 0.71% |
17,687,772
|
|
||
|
CNTA
37
Centessa Pharmaceuticals
CNTA
$4.21B
| $55.6M | 0.68% |
2,291,747
+761,911
|
|
||
|
38
Alkermes
ALKS
$4.77B
| $50.2M | 0.62% |
1,672,356
-3,009,933
|
|
||
|
CMPS
39
Compass Pathways
CMPS
$503M
| $49.9M | 0.61% |
8,707,390
+485,461
|
|
||
40
Cogent Biosciences
COGT
$6.1B
| $49.8M | 0.61% |
+3,467,486
|
|
||
41
Verastem
VSTM
$779M
| $47.9M | 0.59% |
5,426,306
+1,174,690
|
|
||
42
Quest Diagnostics
DGX
$20.4B
| $47.6M | 0.59% |
250,000
-250,000
|
|
||
|
LENZ
43
LENZ Therapeutics
LENZ
$951M
| $40.2M | 0.5% |
863,389
|
|
||
44
RAPT Therapeutics
RAPT
$873M
| $37.9M | 0.47% |
1,470,499
|
|
||
|
ORKA
45
Oruka Therapeutics
ORKA
$1.34B
| $37.4M | 0.46% |
1,945,649
|
|
||
46
Dyne Therapeutics
DYN
$2.94B
| $36.6M | 0.45% |
2,890,567
+1,200,000
|
|
||
47
Crinetics Pharmaceuticals
CRNX
$4.29B
| $36.3M | 0.45% |
872,387
+405,387
|
|
||
48
Aquestive Therapeutics
AQST
$756M
| $34.9M | 0.43% |
+6,250,000
|
|
||
|
ABVX
49
Abivax
ABVX
$9.34B
| $29.7M | 0.37% |
+350,000
|
|
||
50
GE HealthCare
GEHC
$36.1B
| $29.6M | 0.36% |
393,500
-232,500
|
|